X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (29) 29
hiv infections - drug therapy (21) 21
index medicus (16) 16
ccr5 receptor antagonists (13) 13
female (13) 13
infectious diseases (13) 13
male (13) 13
cyclohexanes - therapeutic use (12) 12
maraviroc (12) 12
triazoles - therapeutic use (12) 12
viral load (12) 12
virology (12) 12
adult (11) 11
hiv (11) 11
hiv infections - virology (11) 11
anti-hiv agents - therapeutic use (10) 10
hiv-1 - drug effects (10) 10
immunology (10) 10
middle aged (10) 10
hiv infection (9) 9
cd4 lymphocyte count (8) 8
hiv-1 - genetics (8) 8
infection (8) 8
adolescent (7) 7
aged (7) 7
animals (7) 7
efficacy (7) 7
health aspects (7) 7
hiv infections - immunology (7) 7
hiv-1 (7) 7
human immunodeficiency virus--hiv (7) 7
pharmacology & pharmacy (7) 7
treatment outcome (7) 7
anti-hiv agents - pharmacology (6) 6
ccr5 antagonist (6) 6
cyclohexanes - adverse effects (6) 6
cyclohexanes - pharmacology (6) 6
drug therapy (6) 6
drug therapy, combination (6) 6
hiv fusion inhibitors - therapeutic use (6) 6
rna, viral - blood (6) 6
triazoles - adverse effects (6) 6
triazoles - pharmacology (6) 6
viruses (6) 6
aids (5) 5
double-blind method (5) 5
hiv-1 - isolation & purification (5) 5
inhibitor (5) 5
south africa (5) 5
treatment-experienced patients (5) 5
tropism (5) 5
young adult (5) 5
abridged index medicus (4) 4
amino acid sequence (4) 4
anti-hiv agents - adverse effects (4) 4
anti-hiv agents - pharmacokinetics (4) 4
antiretroviral therapy (4) 4
antiviral agents (4) 4
care and treatment (4) 4
clinical-trials (4) 4
coreceptor usage (4) 4
cyclohexanes - pharmacokinetics (4) 4
genotype (4) 4
hiv fusion inhibitors - adverse effects (4) 4
hiv patients (4) 4
pan troglodytes (4) 4
randomized controlled trials as topic (4) 4
risk (4) 4
therapy (4) 4
triazoles - pharmacokinetics (4) 4
virus diseases (4) 4
aids vaccines - immunology (3) 3
analysis (3) 3
ccr5 (3) 3
clinical trials as topic (3) 3
computer simulation (3) 3
dose-response relationship, drug (3) 3
drug resistance (3) 3
drug resistance, viral (3) 3
entry (3) 3
glycoprotein (3) 3
gp120 (3) 3
hiv-1 - physiology (3) 3
hiv/aids (3) 3
k ze virology (3) 3
molecular sequence data (3) 3
phenotype (3) 3
phylogeny (3) 3
prognostic value (3) 3
receptors, ccr5 - genetics (3) 3
receptors, ccr5 - metabolism (3) 3
research article (3) 3
ritonavir (3) 3
safety (3) 3
subgroup (3) 3
usage (3) 3
virus (3) 3
acquired immune deficiency syndrome--aids (2) 2
aids/hiv (2) 2
anti-hiv agents - administration & dosage (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of the New York Academy of Sciences, ISSN 0077-8923, 06/2015, Volume 1346, Issue 1, pp. 7 - 17
Journal Article
Frontiers in Immunology, ISSN 1664-3224, 2015, Volume 6, p. 277
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2008, Volume 359, Issue 14, pp. 1429 - 1441
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 3/2010, Volume 201, Issue 6, pp. 803 - 813
Background. The MERIT (M̄araviroc versus Ēfavir̄enz īn T̄reatment-Naive Patients) study compared maraviroc and efavirenz, both with zidovudine-lamivudine, in... 
HIV/AIDS | Tropisms | RNA | HIV | Stock options | Response rates | Viruses | Infections | Post hoc | HIV 1 | Virology | INFECTIOUS DISEASES | EFFICACY | SAFETY | MICROBIOLOGY | HIV-1-INFECTED PATIENTS | IMMUNOLOGY | LOPINAVIR-RITONAVIR | THERAPY | VIROLOGICAL FAILURE | RESISTANT HIV-1 | INHIBITOR | CORECEPTOR TROPISM | PLUS | Anti-HIV Agents - pharmacology | Lamivudine - administration & dosage | Cyclohexanes - pharmacology | Humans | Middle Aged | Drug Resistance, Viral | Male | Anti-HIV Agents - standards | Viral Load | Zidovudine - administration & dosage | Young Adult | Cyclohexanes - therapeutic use | Receptors, CCR5 - metabolism | HIV-1 - physiology | Adult | Female | Triazoles - standards | Viral Tropism | Drug Therapy, Combination | CCR5 Receptor Antagonists | Triazoles - therapeutic use | Antiviral Agents - pharmacology | Double-Blind Method | HIV-1 - drug effects | Treatment Outcome | Anti-Retroviral Agents | Benzoxazines - standards | Benzoxazines - therapeutic use | Triazoles - pharmacology | Adolescent | Benzoxazines - pharmacology | Cyclohexanes - standards | HIV Infections - drug therapy | Aged | Drug Combinations | Maraviroc | Patient outcomes | Physiological aspects | Dosage and administration | Genetic aspects | Research | Drug therapy, Combination | Drug therapy | HIV infection | Efavirenz | Chemokines
Journal Article
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2008, Volume 359, Issue 14, pp. 1442 - 1455
In key subgroups of the HIV-infected patients in the MOTIVATE 1 and MOTIVATE 2 studies, a consistent treatment benefit of maraviroc over placebo was seen at 48... 
CCR5 ANTAGONIST | MEDICINE, GENERAL & INTERNAL | EFFICACY | EXPERIENCED HIV-1-INFECTED PATIENTS | TMC125 ETRAVIRINE | ACTIVE ANTIRETROVIRAL THERAPY | DRUG-RESISTANT HIV-1 | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | HEPATITIS-C | PROGNOSTIC VALUE | Triazoles - adverse effects | Humans | Middle Aged | Receptors, CCR5 - genetics | Male | RNA, Viral - blood | Hepatitis B - blood | Viral Load | Hepatitis B - complications | Cyclohexanes - therapeutic use | HIV Infections - immunology | Ethnic Groups | HIV Envelope Protein gp41 - therapeutic use | HIV-1 - chemistry | Hepatitis C - blood | Adult | Female | Hepatitis C - complications | Cyclohexanes - adverse effects | Drug Therapy, Combination | Odds Ratio | CCR5 Receptor Antagonists | Triazoles - therapeutic use | Anti-Retroviral Agents - therapeutic use | Double-Blind Method | HIV Infections - virology | Anti-Retroviral Agents - adverse effects | Genotype | Treatment Outcome | CD4 Lymphocyte Count | HIV Fusion Inhibitors - adverse effects | HIV-1 - genetics | HIV Fusion Inhibitors - therapeutic use | HIV Infections - drug therapy | Transaminases - blood | Aged | Peptide Fragments - therapeutic use | Antiviral agents | Care and treatment | Maraviroc | Comparative analysis | Health aspects | HIV infection | Drug therapy | Drug resistance | Human immunodeficiency virus--HIV | Chemokines | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
AIDS, ISSN 0269-9370, 03/2014, Volume 28, Issue 5, pp. 717 - 725
Journal Article
Journal Article
Journal Article